Editorial |

Targeting the Host to Control an Infection Disorder

Kasturi Haldar, PhD
Arch Intern Med. 2008;168(19):2067-2068. doi:10.1001/archinte.168.19.2067.
Text Size: A A A
Published online


Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, which catalyzes the production of mevalonate from HMG CoA, the first and rate-limiting step in cholesterol biosynthesis in mammalian cells. Inhibition of HMG CoA reductase in the liver induces production of low-density lipoprotein receptors and, thus, clearance of circulating low-density lipoprotein, resulting in lower cholesterol levels.1,2 Historically, the use of statins revolutionized cholesterol management and reduction of cardiovascular risk.3 However, in addition to their cholesterol-lowering effects and benefit in preventing stroke, coronary heart disease, myocardial infarction, and peripheral artery disease, statins also seem to reduce inflammation in patients with cancer, dementia, severe infection, and pulmonary hypertension.4 In this issue of the Archives, Thomsen et al5 present evidence that statin use is associated with an improved prognosis after severe pneumonia. These data suggest a substantial decrease in mortality with statin use. C-reactive protein levels were lower in statin users compared with nonusers, which suggests that statins reduce inflammation.

Figures in this Article



Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Pathway of cholesterol biosynthesis. CoA indicates coenzyme A; HMG CoA, 3-hydroxy-3-methylglutaryl CoA.

Graphic Jump Location




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles